May increase the unbound fraction of highly protein-bound therapies, altering their effectiveness and safety profiles; may increase ergot-related adverse effects or reduce ergot effectiveness for migraines if co-administered within 6 hrs of ergot-related drugs; extensively metabolized by CYP3A4. Use caution when co-administering strong inhibitors, inducers or substrates for CYP3A4.